NEW YORK & MIAMI — The Parkinson's Foundation is pleased to announce a $1.2 million investment in 27 career development and fellowship grants to support the work of promising early career scientists in the field of Parkinson's.
"We are proud to continue our long-standing tradition of nurturing the careers of the next generation of Parkinson's researchers," said John L. Lehr, chief executive officer of the Parkinson's Foundation. "Their innovative ideas may one day transform the field for millions worldwide."
Every year, the Parkinson's Foundation invests $4 million in a diverse research portfolio. A significant portion of that amount is directed toward career development grants and fellowships. The grant programs, which range from three months to two years in length, provide students, and postdoctoral researchers and clinicians with the opportunity to test new ideas, work with mentors and transition into senior leaders.
One standout grant recipient this year is Xi Chen, Ph.D., of the Van Andel Research Institute, who is using a $100,000 postdoctoral fellowship to study an emerging area of genetics: the VPS35 gene. The role of the VPS35 gene, which was discovered to play a part in Parkinson's, is not well understood. Working under the guidance of mentor Darren Moore, Ph.D., whose early research was also funded by the Parkinson's Foundation, Dr. Chen will study a mouse model to understand how VPS35 might interact with proteins and brain cells and potentially lead to Parkinson's symptoms.
This understanding of the VPS35 gene may help to develop new drugs to prevent or treat Parkinson's in the future.
"As a former grantee, I know firsthand that the Parkinson's Foundation grant funding can help to launch a career in Parkinson's," Dr. Moore said. "In today's funding environment, the foundation's grants fill a critical gap and ensure that the best research continues."
"The Parkinson's Foundation recognizes that we must support the creativity and ingenuity of the next generation in order to make advances," said James Beck, Ph.D., chief scientific officer of the Parkinson's Foundation. "We are excited to track results from Dr. Chen and others whose work holds potential to help us end Parkinson's."
Parkinson's Foundation research investments are selected through a competitive application process reviewed by its Scientific Advisory Board, which includes scientific experts and foundation-trained patient advocates.
The foundation's latest career development and fellowship grants are listed below. Additional information is available about research we fund.
Clinical Training Fellowships | $460,000
Columbia University Medical Center°
Deepak Gupta, M.D.*
Devin Hall, M.D.*
Krithi Irmandy, M.D., Ph.D.
Lan Luo, M.D.**
Sarah O'Shea, M.D.*
Rush University Medical Center°
Avram Fraint, M.D.*
Anjali Gera, M.D.
Postdoctoral Research Fellowships | $275,000
D620N VPS35 Knock-In Mice: A New Model of Familial Parkinson's Disease
Xi Chen, Ph.D., Mentor: Darren Moore, Ph.D., Van Andel Research Institute
Mitochondrial Protein Homeostasis in Peripheral Axons
Jill Falk, Ph.D., Mentor: Thomas Schwarz, Ph.D., Harvard Medical School/Children's Hospital Boston
Human A chemical messenger (neurotransmitter) that regulates movement and emotions. Neuronal Progenitors for PD Therapeutic Development
Xiang Li, Ph.D., Mentor: Su-Chun Zhang, Ph.D., University of Wisconsin-Madison
Investigation of the Role of the Neuronal NLRP3 Inflammasome in PD
Nikhil Panicker, Ph.D., Mentor: Ted Dawson, M.D., Ph.D., Johns Hopkins School of Medicine°
Role of Cerebellum on Area of the brain responsible for producing smooth, continuous muscular actions, including starting and stopping movements; also responsible for elements of thinking. Cortical Network in Parkinson's Disease
Nicholas Strzalkowski, Ph.D., Mentor: Zelma Kiss, M.D., Ph.D., F.R.C.S.C., University of Calgary, Canada°
Collaborative Fellowships | $138,000
Clinical Research Training Fellowship
(In partnership with the American Brain Foundation / American Academy of Neurology)
Wearable Devices and Smartphone Apps in PD
Michelle Fullard, M.D., Mentor: Alice Chen-Plotkin, M.D., University of Pennsylvania°
Parkinson's Foundation-PSG Mentored Clinical Research Award
(In partnership with the Parkinson Study Group)
Automated Closed-looped Algorithm to Rapidly Optimize DBS Settings for PD
Matthew Petrucci, Ph.D., Mentors: Paul Tuite, M.D., Colum MacKinnon, Ph.D., and Theoden Netoff, Ph.D., University of Minnesota
Parkinson's Foundation-HHMI Medical Fellowship
(In partnership with the Howard Hughes Medical Institute)
Molecular and Electrophysiological Characterization of Dbx1+ GPe Neurons
Zachary Abecassis, M.D., Mentor: C Savio Chan, Ph.D., candidate, Northwestern University, The Feinberg School of Medicine°
Parkinson's Foundation-APDA Summer Student Fellowships | $60,000
(In partnership with the American Parkinson Disease Association)
Development of Non-invasive Immunotherapy for PD: Intranasal Targeting of Immunoglobulin G Antibodies to the CNS
Sam Boroumand, Mentor: Robert Thorne, Ph.D., University of Wisconsin-Madison
Brain Atrophy and the Progression of Cognitive Decline in Parkinson's
Carolina Cao, Mentor: Meghan Campbell, Ph.D., Washington University School of Medicine
Role of Lactate Shuttling in Motor Control of GPe Neurons
Isabel Fan, Mentor: C. Savio Chan, Ph.D., Northwestern University°
The Interaction of Two Parkinson's Disease Genes FBX07 and PINK1
Dima Hage, Mentor: David Park, Ph.D., University of Ottawa
Modulating SNr Neuronal Activity in PD and LID
Yong Hu, M.D., Ph.D. Student, Mentor: Un Jung Kang, M.D., Columbia University Medical Center°
Characterizing Microsaccades as a Novel Diagnostic Biomarker for PD
Sarah Kang, Mentor: Aasef Shaikh, M.D., Ph.D., Louis Stokes Cleveland Veterans Affairs Medical Center
Stability, Activity and Mutation Effects In Human and Mouse LRRK2
Rebekah Langston, Mentor: Mark Cookson, Ph.D., National Institutes of Health
Using Human Neurons to Delineate the Role of the Unfolded Protein Response in Parkinson's Disease
Lotus Lum, Mentor: Scott Oakes, M.D., University of California, San Francisco°
Mapping of Cortical Networks Activated by Dorsal vs. Ventral STN-DBS
Aarathi Minisandram, Mentor: Todd Herrington, M.D., Ph.D., Massachusetts General Hospital°
Effect of The medication most commonly given to control the movement symptoms of Parkinson’s, usually with carbidopa. It is converted in the brain into dopamine. on the Consolidation of Learning in People with PD
Zhen-Yi Andy Ou, Mentor: Madeleine Sharp, M.D., M.Sc., Montreal Neurological Hospital
Nuclear Membrane Abnormalities in a Symptomatic Dystonia Model
CheyAnne Rivera, Mentor: William Dauer, M.D., University of Michigan
Novel Neuro-ophthalmic Clinical Markers for Parkinson's Disease
Caroline Yu, Mentor: Y. Joyce Liao, M.D., Ph.D., Stanford School of Medicine
* Denotes second year of funding
** Denotes third year of funding
°Denotes Parkinson's Foundation Center of Excellence
About the Parkinson's Foundation
The Parkinson's Foundation is working toward a world without Parkinson's disease. Formed by the merger of National Parkinson Foundation (NPF) and the Parkinson's Disease Foundation (PDF), the mission of the Parkinson's Foundation is to invest in promising scientific research that will end Parkinson's disease and improve the lives of people with Parkinson's, and their families, through improved treatments, support and the best care. For more information, visit www.parkinson.org, or call (800) 4PD-INFO (473-4636).
About Parkinson's Disease (PD)
Affecting an estimated one million Americans and 10 million worldwide, PD is the second-most common neurodegenerative disease after Alzheimer's and is the 14th-leading cause of death in the United States. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression) as well as non-motor symptoms (e.g., A mood disorder whose symptoms can include a persistent sad or empty mood, feelings of hopelessness or pessimism, irritability and loss of interest or pleasure in previously enjoyable activities. and A feeling of nervousness, worried thoughts and physical distress.). There is no cure for PD and 60,000 new cases are diagnosed each year in the United States alone.
# # #
Editor's Note: Interviews are available upon request